Yaşlı Hipertensif Hastalarda Kullanılan Beta Blokerler Cilt Kanserlerinin Riski Azaltır Mı?

Yıl 2019, , 311 - 314, 31.12.2019

Habibullah Aktas Erdinc Terzi

https://doi.org/10.16899/jcm.553773

Öz

Beta blokerler çoğunlukla yıllarca kardiyovasküler sağlık sorunlarının tedavisinde kullanılan
ilaçlardır.Diğer bilinen endikasyonları migren, anksiyete, tirotoksikoz ve infantil hemanjiyomlardır.
Bunlara ek olarak, son çalışmalar, muhtemelen tümör ilerlemesi için gerekli olan adrenerjik ve
anjiyogenez bloke edici etkileri nedeniyle antikanser özelliklere sahip olduğunu göstermektedir.
Prostat, meme, yumurtalık, küçük hücreli dışı akciğer kanserleri veya melanoması olan hastaların
beta bloker tedavilerden yararlandıkları gösterilmiştir. Bu verilere bağlı olarak, son iki yılda
premalign cilt lezyonları ve melanom dışı cilt kanserli hastaların antihipertansif ilaç öyküsünü
araştırdık. Çalışmamızda antihipertansif ajan olarak beta bloker kullanan hastaların daha az solar
keratoz ve bazal hücre kanserleri olduğunu gördük.

Could beta blocker use in elderly hypertensive patients reduce risk of skin cancers?

Öz

Beta
blokers are commonly used medications mainly in the treatment of
cardiovascular health problems for years.Other known indications are
migraine,anxiety,thyrotoxicosis and infantile hemangiomas.In addition
to these,recent studies showes they have anticancer properties
probably due to their adrenergic and angiogenesis blocking effects
which are essential for tumor progression.Patients with
prostate,breast,ovarian,non-small cell lung cancers or melanoma were
demonstrated getting benefit from beta blocer treatments.Depending on
these data,we searched antihypertensive drug history of patients with
premalignant skin lesions and non-melanoma akin cancers at past two
years.We observed that patients using beta blockers as
antihypertensive agent had less solar keratosis and basal cell
cancers during the our study.

Anahtar Kelimeler

Beta blockers, Skin cancer

Kaynakça

• 1.Schmitt JV,Miot HA.Actinic keratosis: a clinical and epidemiological revision.An Bras Dermatol.2012; 87,425-34.
• 2.Sun Z.Aging, arterial stiffness, and hypertension.Hypertension.2015;65,252-6.
• 3.Sipahi I,Debanne SM,Rowland DY,et al.Angiotensin-receptor blockade and risk ofcancer: meta-analysis of randomised controlled trials.Lancet Oncol.2010 ;11,627-36.
• 4.Bangalore S,Kumar S,Kjeldsen SE,et al.Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.Lancet Oncol.2011;12,65-82.
• 5.Akbar S,Alsharidah MS.Are beta blockers new potential anticancer agents?Asian Pac J Cancer Prev.2014;15,9567-74.
• 6.Melhem-Bertrandt A,et al.Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.J Clin Oncol.2011;29,2645-52.
• 7.De Giorgi V, Gandini S, Grazzini M, et al.β-blockers: a new and emerging treatment for melanoma.Recenti Prog Med.2012;103,11-6.
• 8.Hwa YL, Shi Q, Kumar SK, Lacy MQ, et al.Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. Am J Hematol.2017;92,50-55.
• 9.Grytli HH, Fagerland MW, Fosså SD,et al.Use of β-blockers is associated with prostate cancer specific survival in prostate cancer patients on androgen deprivation therapy.Prostate,2013;73,250–607.
• 10.Huang KM,et al.Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation InducedSkin Carcinogenesis.Cancer Prev Res (Phila).2017;10,598-606.
• 11.Joel L. Cohen.Actinic Keratosis Treatment as a Key Component of Preventive Strategies for Nonmelanoma Skin Cancer.J Clin Aesthet Dermatol.2010;3, 39–44.
• 12.Robles NR, Macias JF.Hypertension in the elderly.Cardiovasc Hematol Agents Med Chem.2015;12,135.
• 13.Weir MR.Beta-blockers in the treatment of hypertension: are there clinically relevant differences?Postgrad.2009;121:90-8.
• 14.Akbar S,Alorainy MS.The current status of beta blockers' use in the management of hypertension.Saudi Med J.2014;35,1307-17.
• 15.Pantziarka P,Bouche G,Sukhatme V,et al.Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.E cancer medical science.2016;12,10,680.
• 16.He JJ et al. Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma.Oncol Lett.2017;14,3846-3852.
• 17.Lin X,Luo K,Lv Z,Huang J.β-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice.Hepatogastroenterology.2012;59,584-8.
• 18.Hondermarck H,Jobling P.The Sympathetic Nervous System Drives Tumor Angiogenesis.Trends Cancer.2018;4,93-94.
• 19.Chang A, et al.Prevention of skin carcinogenesis by the β-blocker carvedilol.Cancer Prev Res(Phila).2015;8,27-36.
• 20.Gandini S,et al.Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis.Crit Rev Oncol Hematol.2018;122:1-9.
• 21.Hank et al. Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studiesPharmacoepidemiol Drug Saf. 2018;27,279-288.
• 22.De Giorgi V, Grazzini M, Gandini S, et al.Treatment with β-blockers and reduced disease progression in patients with thick melanoma.Arch Intern Med.2011;171,779–81.
• 23.Lemeshow S, Sorensen HT, Phillips G, et al. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.Cancer Epidemiol Biomarkers Prev.2011;20,2273–9.
• 24.de Vries E, Trakatelli M, Kalabalikis D, et al.Known and potential new risk factors for skin cancer in European populations: a multicentre case–control study. Br J Dermatol.2012;167(Suppl 2),1–13.
• 25.Lai V,Cranwell W,Sinclair R.Epidemiology of skin cancer in the mature patient.Clin Dermatol.2018;36,167-176.